The U.S. Food and Drug Administration has issued letters to Amgen Inc. indicating that dialysis clinics can limit distribution of medication guides for Aranesp and Epogen to  when a patient initiates therapy with one of the drugs, or when the guide is materially revised or updated.

The letters can be downloaded here:

Aranesp

Epogen/Procrit